INBS (Intelligent Bio Solutions) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INBS Intelligent Bio Solutions Inc INBS
48 GF Score
Price $2.25
GF Value $2.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Intelligent Bio Solutions Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

INBS
48GF Score
Intelligent Bio Solutions Inc INBS
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Intelligent Bio Solutions (INBS) Overvalued in 2026?

Based on GuruFocus' analysis, Intelligent Bio Solutions stock appears to be undervalued. The current stock price of $2.25 is trading 13.8% below its estimated GF Value™ of $2.61. GuruFocus considers Intelligent Bio Solutions to be Modestly Undervalued.

Key valuation signals for INBS:

  • Dividends Received:
  • GF Value™: $2.61 vs. price of $2.25 (13.8% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the INBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intelligent Bio Solutions Business Description

Address 135 West, 41ST Street, 5th Floor, New York, NY, USA, 10036
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
48GF Score

Get the complete analysis for INBS

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.25
Price
$2.61
GF Value